Medical Developments International (MVP) H2 2024 earnings summary

Executive summary

• FY 2024 saw a 3% increase in group revenue to $33.2 million, with improved margins, earnings, and cash flow, and a gross margin up 5 percentage points to 74%.

• Strategic priorities advanced, including margin improvement, Penthrox penetration in Australian hospitals (+30% volume), record in-market volumes in Europe, and respiratory franchise growth in the U.S.

• Operational efficiency initiatives reduced costs by approximately $5 million, with further $3–4 million in cost reductions expected in FY 2025.

• A $10 million capital raise in August 2024 strengthened the balance sheet and funded growth initiatives.

• The MAGPIE pediatric study supports regulatory submissions to expand Penthrox's age indication in Europe.

Financial highlights

• Gross margin improved to 74%, mainly due to higher pricing in Australia.

• Underlying EBIT improved by $6.6 million (+36%) to a loss of $11.6 million year-over-year.

• Net loss after tax was $41 million, impacted by non-cash asset impairments and derecognition of tax losses.

• Free cash flow improved by $10.2 million; cash at period end was $9.7 million, rising to $18.9 million post-capital raise.

• Pain Management segment revenue grew 4% to $21.3 million; Respiratory segment revenue up 1% to $11.9 million.

Outlook and guidance

• FY 2025 will focus on further margin improvement, targeting an additional $3–4 million in earnings benefits.

• Positive operating cash flows are expected by the end of FY 2025.

• Underlying EBIT in FY 2025 is expected to be strongly improved, driven by higher Penthrox prices and operational efficiencies.

• CapEx for FY 2025 is projected at $1.5–2.0 million.